CD8A and glioblastoma: The motor-clutch-based CMS predicts that the former is more sensitive, and may be a better strategy, although it will be important to assess the effects of drugs on immune cells in the glioblastoma tumor microenvironment, especially antitumoral CD8 + T cells.